{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T10:45:40Z","timestamp":1782211540913,"version":"3.54.5"},"reference-count":70,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2017,5,20]],"date-time":"2017-05-20T00:00:00Z","timestamp":1495238400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Acta Neurol Belg"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1007\/s13760-017-0794-7","type":"journal-article","created":{"date-parts":[[2017,5,20]],"date-time":"2017-05-20T03:26:18Z","timestamp":1495250778000},"page":"821-827","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Multiple sclerosis treatment with fingolimod: profile of non-cardiologic adverse events"],"prefix":"10.1007","volume":"117","author":[{"given":"Yara Dadalti","family":"Fragoso","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,5,20]]},"reference":[{"key":"794_CR1","doi-asserted-by":"publisher","first-page":"CD009371","DOI":"10.1002\/14651858.CD009371.pub2","volume":"4","author":"L Mantia La","year":"2016","unstructured":"La Mantia L, Tramacere I, Firwana B, Pacchetti I, Palumbo R, Filippini G (2016) Fingolimod for relapsing-remitting multiple sclerosis. Cochrane Database Syst Rev 4:CD009371. doi:\n                        10.1002\/14651858.CD009371.pub2","journal-title":"Cochrane Database Syst Rev"},{"key":"794_CR2","doi-asserted-by":"publisher","first-page":"673","DOI":"10.2165\/11207350-000000000-00000","volume":"25","author":"LJ Scott","year":"2011","unstructured":"Scott LJ (2011) Fingolimod: a review of its use in the management of relapsing-remitting multiple sclerosis. CNS Drugs 25:673\u2013698. doi:\n                        10.2165\/11207350-000000000-00000","journal-title":"CNS Drugs"},{"key":"794_CR3","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1517\/14740338.2014.920820","volume":"13","author":"MD Ward","year":"2014","unstructured":"Ward MD, Jones DE, Goldman MD (2014) Overview and safety of fingolimod hydrochloride use in patients with multiple sclerosis. Expert Opin Drug Saf. 13:989\u2013998. doi:\n                        10.1517\/14740338.2014.920820","journal-title":"Expert Opin Drug Saf."},{"key":"794_CR4","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1056\/NEJMoa0909494","volume":"362","author":"L Kappos","year":"2010","unstructured":"Kappos L, Radue E-W, O\u2019Connor P, Polman C, Hohlfeld R, Calabresi P, Selmaj K, Agoropoulou C, Leyk M, Zhang-Auberson L, Burtin P, FREEDOMS Study Group (2010) A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med 362:387\u2013401. doi:\n                        10.1056\/NEJMoa0909494","journal-title":"N Engl J Med"},{"key":"794_CR5","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1056\/NEJMoa0907839","volume":"362","author":"JA Cohen","year":"2010","unstructured":"Cohen JA, Barkhof F, Comi G, Hartung HP, Khatri BO, Montalban X, Pelletier J, Capra R, Gallo P, Izquierdo G, Tiel-Wilck K, de Vera A, Jin J, Stites T, Wu S, Aradhye S, Kappos L, TRANSFORMS Study Group (2010) Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med 362:402\u2013415. doi:\n                        10.1056\/NEJMoa0907839","journal-title":"N Engl J Med"},{"key":"794_CR6","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.msard.2016.04.002","volume":"8","author":"A Meissner","year":"2016","unstructured":"Meissner A, Limmroth V (2016) Update on the cardiovascular profile of fingolimod in the therapy of relapsing-remitting multiple sclerosis (MS. Mult Scler Relat Disord. 8:19\u201326. doi:\n                        10.1016\/j.msard.2016.04.002","journal-title":"Mult Scler Relat Disord."},{"key":"794_CR7","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1212\/WNL.0b013e31821043b5","volume":"76","author":"A Uccelli","year":"2011","unstructured":"Uccelli A, Ginocchio F, Mancardi GL, Bassetti M (2011) Primary varicella zoster infection associated with fingolimod treatment. Neurology. 76:1023\u20131024. doi:\n                        10.1212\/WNL.0b013e31821043b5","journal-title":"Neurology."},{"key":"794_CR8","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1016\/j.jiac.2016.07.011","volume":"22","author":"H Hagiya","year":"2016","unstructured":"Hagiya H, Yoshida H, Shimizu M, Motooka D, Nakamura S, Iida T, Yamamoto N, Akeda Y, Tomono K (2016) Herpes zoster laryngitis in a patient treated with fingolimod. J Infect Chemother 22:830\u2013832. doi:\n                        10.1016\/j.jiac.2016.07.011","journal-title":"J Infect Chemother"},{"key":"794_CR9","doi-asserted-by":"publisher","first-page":"2002","DOI":"10.1212\/WNL.0b013e3182735d00","volume":"79","author":"JN Ratchford","year":"2012","unstructured":"Ratchford JN, Costello K, Reich DS, Calabresi PA (2012) Varicella-zoster virus encephalitis and vasculopathy in a patient treated with fingolimod. Neurology 79:2002\u20132004. doi:\n                        10.1212\/WNL.0b013e3182735d00","journal-title":"Neurology"},{"key":"794_CR10","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1212\/WNL.0000000000001109","volume":"84","author":"NP Issa","year":"2015","unstructured":"Issa NP, Hentati A (2015) VZV encephalitis that developed in an immunized patient during fingolimod therapy. Neurology 84:99\u2013100. doi:\n                        10.1212\/WNL.0000000000001109","journal-title":"Neurology"},{"key":"794_CR11","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.eimc.2014.04.007","volume":"33","author":"MM Kawiorski","year":"2015","unstructured":"Kawiorski MM, Viedma-Guiard E, Costa-Frossard L, Corral I (2015) Polydermatomal perineal and gluteal herpes zoster infection in a patient on fingolimod treatment. Enferm Infecc Microbiol Clin 33:138\u2013139. doi:\n                        10.1016\/j.eimc.2014.04.007","journal-title":"Enferm Infecc Microbiol Clin"},{"key":"794_CR12","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1212\/WNL.0000000000001556","volume":"84","author":"T Tully","year":"2015","unstructured":"Tully T, Barkley A, Silber E (2015) Kaposi sarcoma in a patient with relapsing-remitting multiple sclerosis receiving fingolimod. Neurology 84:1999\u20132001. doi:\n                        10.1212\/WNL.0000000000001556","journal-title":"Neurology"},{"key":"794_CR13","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1001\/jamaneurol.2014.3065","volume":"72","author":"AM Arvin","year":"2015","unstructured":"Arvin AM, Wolinsky JS, Kappos L, Morris MI, Reder AT, Tornatore C, Gershon A, Gershon M, Levin MJ, Bezuidenhoudt M, Putzki N (2015) Varicella-zoster virus infections in patients treated with fingolimod: risk assessment and consensus recommendations for management. JAMA Neurol 72:31\u201339. doi:\n                        10.1001\/jamaneurol.2014.3065","journal-title":"JAMA Neurol"},{"key":"794_CR14","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1590\/0004-282X20150027","volume":"73","author":"YD Fragoso","year":"2015","unstructured":"Fragoso YD, Brooks JB (2015) A specific vaccine to protect patients with multiple sclerosis from herpes zoster. Arq Neuropsiquiatr 73:370. doi:\n                        10.1590\/0004-282X20150027","journal-title":"Arq Neuropsiquiatr"},{"key":"794_CR15","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1001\/jamaneurol.2015.4259","volume":"73","author":"AK Forrestel","year":"2016","unstructured":"Forrestel AK, Modi BG, Longworth S, Wilck MB, Micheletti RG (2016) Primary cutaneous Cryptococcus in a patient with multiple sclerosis treated with fingolimod. JAMA Neurol 73:355\u2013356. doi:\n                        10.1001\/jamaneurol.2015.4259","journal-title":"JAMA Neurol"},{"key":"794_CR16","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.msard.2016.07.015","volume":"9","author":"E Grebenciucova","year":"2016","unstructured":"Grebenciucova E, Reder AT, Bernard JT (2016) Immunologic mechanisms of fingolimod and the role of immunosenescence in the risk of cryptococcal infection: a case report and review of literature. Mult Scler Relat Disord 9:158\u2013162. doi:\n                        10.1016\/j.msard.2016.07.015","journal-title":"Mult Scler Relat Disord"},{"key":"794_CR17","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1001\/jamaneurol.2015.1746","volume":"72","author":"L Achtnichts","year":"2015","unstructured":"Achtnichts L, Obreja O, Conen A, Fux CA, Nedeltchev K (2015) Cryptococcal meningoencephalitis in a patient with multiple sclerosis treated with fingolimod. JAMA Neurol 72:1203\u20131205. doi:\n                        10.1001\/jamaneurol.2015.1746","journal-title":"JAMA Neurol"},{"key":"794_CR18","doi-asserted-by":"crossref","first-page":"3383","DOI":"10.2169\/internalmedicine.55.7255","volume":"55","author":"H Seto","year":"2016","unstructured":"Seto H, Nishimura M, Minamiji K, Miyoshi S, Mori H, Kanazawa K, Yasuda H (2016) Disseminated Cryptococcosis in a 63-year-old patient with multiple sclerosis treated with fingolimod. Intern Med 55:3383\u20133386","journal-title":"Intern Med"},{"key":"794_CR19","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1212\/WNL.0000000000001929","volume":"85","author":"D Huang","year":"2015","unstructured":"Huang D (2015) Disseminated cryptococcosis in a patient with multiple sclerosis treated with fingolimod. Neurology 85:1001\u20131003. doi:\n                        10.1212\/WNL.0000000000001929","journal-title":"Neurology"},{"key":"794_CR20","first-page":"331","volume":"22","author":"A Marrone","year":"2014","unstructured":"Marrone A, Signoriello E, Alfieri G, Dalla Mora L, Rinaldi L, Rainone I, Adinolfi LE, Lus G (2014) Epstein Barr virus infection reactivation as a possible trigger of primary biliary cirrhosis-like syndrome in a patient with multiple sclerosis in the course of fingolimod treatment. Infez Med 22:331\u2013336","journal-title":"Infez Med"},{"key":"794_CR21","doi-asserted-by":"publisher","first-page":"2420","DOI":"10.1002\/hep.26158","volume":"56","author":"EY Chen","year":"2012","unstructured":"Chen EY, Baum K, Collins W, L\u00f6ve A, Merz M, Olafsson S, Bj\u00f6rnsson ES, Lee WM (2012) Hepatitis E masquerading as drug-induced liver injury. Hepatology 56:2420\u20132423. doi:\n                        10.1002\/hep.26158","journal-title":"Hepatology"},{"key":"794_CR22","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.msard.2016.08.003","volume":"9","author":"A Tagawa","year":"2016","unstructured":"Tagawa A, Ogawa T, Tetsuka S, Otsuka M, Hashimoto R, Kato H, Ando K, Tanabe H (2016) Hepatitis C virus (HCV) reactivation during fingolimod treatment for relapsing and remitting multiple sclerosis. Mult Scler Relat Disord 9:155\u2013157. doi:\n                        10.1016\/j.msard.2016.08.003","journal-title":"Mult Scler Relat Disord"},{"key":"794_CR23","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1177\/1352458516629560","volume":"22","author":"V Behle","year":"2016","unstructured":"Behle V, Wobser M, Goebeler M, Stoevesandt J (2016) Extensive molluscum contagiosum virus infection in a young adult receiving fingolimod. Mult Scler 22:969\u20139671. doi:\n                        10.1177\/1352458516629560","journal-title":"Mult Scler"},{"key":"794_CR24","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1177\/1352458514555788","volume":"21","author":"AK Artemiadis","year":"2015","unstructured":"Artemiadis AK, Nikolaou G, Kolokythopoulos D, Tegos N, Terentiou A, Triantafyllou N, Papanastasiou I (2015) Visceral leishmaniasis infection in a fingolimod-treated multiple sclerosis patient. Mult Scler 21:795\u2013796. doi:\n                        10.1177\/1352458514555788","journal-title":"Mult Scler"},{"key":"794_CR25","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.msard.2017.01.006","volume":"12","author":"JR Berger","year":"2017","unstructured":"Berger JR (2017) Classifying PML risk with disease modifying therapies. Mult Scler Relat Disord. 12:59\u201363. doi:\n                        10.1016\/j.msard.2017.01.006","journal-title":"Mult Scler Relat Disord."},{"key":"794_CR26","doi-asserted-by":"publisher","first-page":"1843","DOI":"10.1212\/WNL.0000000000002654","volume":"86","author":"TV Gyang","year":"2016","unstructured":"Gyang TV, Hamel J, Goodman AD, Gross RA, Samkoff L (2016) Fingolimod-associated PML in a patient with prior immunosuppression. Neurology. 86:1843\u20131845. doi:\n                        10.1212\/WNL.0000000000002654","journal-title":"Neurology."},{"key":"794_CR27","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1590\/0004-282X20160090","volume":"74","author":"YD Fragoso","year":"2016","unstructured":"Fragoso YD, Alves-Leon SV, Becker J, Brooks JB, Correa EC, Damasceno A, Gama PD, Gama RA, Matta AP, Maciel EP, Winckler TC (2016) Safety of switching from natalizumab straight into fingolimod in a group of JCV-positive patients with multiple sclerosis. Arq Neuropsiquiatr 74:650\u2013652. doi:\n                        10.1590\/0004-282X20160090","journal-title":"Arq Neuropsiquiatr"},{"key":"794_CR28","doi-asserted-by":"publisher","first-page":"987","DOI":"10.2147\/PPA.S65708","volume":"8","author":"C Zecca","year":"2014","unstructured":"Zecca C, Caporro M, Gy\u00f6rik S, Gobbi C (2014) Life-threatening asthma attack during prolonged fingolimod treatment: case report. Patient Prefer Adherence 8:987\u2013989. doi:\n                        10.2147\/PPA.S65708","journal-title":"Patient Prefer Adherence"},{"key":"794_CR29","doi-asserted-by":"publisher","first-page":"1792","DOI":"10.1177\/1352458514531844","volume":"20","author":"JA Rossum van","year":"2014","unstructured":"van Rossum JA, Looysen EE, Daniels JM, Killestein J (2014) Fingolimod-induced asthma deterioration in a patient with relapsing-remitting multiple sclerosis. Mult Scler 20:1792\u20131793. doi:\n                        10.1177\/1352458514531844","journal-title":"Mult Scler"},{"key":"794_CR30","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.msard.2016.06.005","volume":"9","author":"A Bianco","year":"2016","unstructured":"Bianco A, Patanella AK, Nociti V, De Fino C, Lucchini M, Savio FL, Rossini PM, Mirabella M (2016) Severe dyspnoea with alteration of the diffusion capacity of the lung associated with fingolimod treatment. Mult Scler Relat Disord 9:11\u201313. doi:\n                        10.1016\/j.msard.2016.06.005","journal-title":"Mult Scler Relat Disord"},{"key":"794_CR31","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1016\/j.jns.2014.11.008","volume":"348","author":"J Flores","year":"2015","unstructured":"Flores J, Rito Y, Torres G, Jung H, Trevi\u00f1o-Frenk I, Corona T (2015) Hypothyroidism in multiple sclerosis patient during fingolimod treatment. J Neurol Sci 348:272\u2013273. doi:\n                        10.1016\/j.jns.2014.11.008","journal-title":"J Neurol Sci"},{"key":"794_CR32","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1111\/head.12526","volume":"55","author":"YD Fragoso","year":"2015","unstructured":"Fragoso YD, Adoni T, Gomes S, Goncalves MV, Matta AP, Mendes MF, Siquineli F (2015) Persistent headache in patients with multiple sclerosis starting treatment with fingolimod. Headache 55:578\u2013579. doi:\n                        10.1111\/head.12526","journal-title":"Headache"},{"key":"794_CR33","doi-asserted-by":"publisher","first-page":"39","DOI":"10.3389\/fneur.2015.00039","volume":"6","author":"H Lind\u00e5","year":"2015","unstructured":"Lind\u00e5 H, von Heijne A (2015) A case of posterior reversible encephalopathy syndrome associated with Gilenya(\u00ae) (fingolimod) treatment for multiple sclerosis. Front Neurol 6:39. doi:\n                        10.3389\/fneur.2015.00039","journal-title":"Front Neurol"},{"key":"794_CR34","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1177\/1352458515600249","volume":"21","author":"M Kraemer","year":"2015","unstructured":"Kraemer M, Weber R, Herold M, Berlit P (2015) Reversible cerebral vasoconstriction syndrome associated with fingolimod treatment in relapsing-remitting multiple sclerosis three months after childbirth. Mult Scler 21:1473\u20131475. doi:\n                        10.1177\/1352458515600249","journal-title":"Mult Scler"},{"key":"794_CR35","first-page":"1","volume":"23","author":"S Belliston","year":"2016","unstructured":"Belliston S, Sundararajan J, Hammond N, Newell K, Lynch S (2016) Reversible cerebral vasoconstriction syndrome in association with fingolimod use. Int J Neurosci 23:1\u20134","journal-title":"Int J Neurosci"},{"key":"794_CR36","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1212\/01.wnl.0000344567.51394.e3","volume":"72","author":"F Leypoldt","year":"2009","unstructured":"Leypoldt F, M\u00fcnchau A, Moeller F, Bester M, Gerloff C, Heesen C (2009) Hemorrhaging focal encephalitis under fingolimod (FTY720) treatment: a case report. Neurology 72:1022\u20131024. doi:\n                        10.1212\/01.wnl.0000344567.51394.e3","journal-title":"Neurology"},{"key":"794_CR37","doi-asserted-by":"publisher","first-page":"47281","DOI":"10.1074\/jbc.M306896200","volume":"21","author":"T Sanchez","year":"2003","unstructured":"Sanchez T, Estrada-Hernandez T, Paik JH, Wu MT, Venkataraman K, Brinkmann V, Claffey K, Hla T (2003) Phosphorylation and action of the immunomodulator FTY720 inhibits vascular endothelial cell growth factor-induced vascular permeability. J Biol Chem 21:47281\u201347290. doi:\n                        10.1074\/jbc.M306896200","journal-title":"J Biol Chem"},{"key":"794_CR38","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1111\/aas.12130","volume":"57","author":"C Lundblad","year":"2013","unstructured":"Lundblad C, Axelberg H, Gr\u00e4nde PO (2013) Treatment with the sphingosine-1phosphate analogue FTY720 reduces loss of plasma volume during experimental sepsis in the rat. Acta Anaesthesiol Scand 57:713\u2013718. doi:\n                        10.1111\/aas.12130","journal-title":"Acta Anaesthesiol Scand"},{"key":"794_CR39","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1161\/01.RES.0000164321.91452.00","volume":"29","author":"M T\u00f6lle","year":"2005","unstructured":"T\u00f6lle M, Levkau B, Keul P, Brinkmann V, Giebing G, Sch\u00f6nfelder G, Sch\u00e4fers M, von Wnuck Lipinski K, Jankowski J, Jankowski V, Chun J, Zidek W, Van der Giet M (2005) Immunomodulator FTY720 Induces eNOS-dependent arterial vasodilatation via the lysophospholipid receptor S1P3. Circ Res 29:913\u2013920. doi:\n                        10.1161\/01.RES.0000164321.91452.00","journal-title":"Circ Res"},{"key":"794_CR40","doi-asserted-by":"publisher","first-page":"2022","DOI":"10.1212\/WNL.0b013e3181e3972b","volume":"74","author":"A Schwarz","year":"2010","unstructured":"Schwarz A, Korporal M, Hosch W, Max R, Wildemann B (2010) Critical vasospasm during fingolimod (FTY720) treatment in a patient with multiple sclerosis. Neurology 74:2022\u20132024. doi:\n                        10.1212\/WNL.0b013e3181e3972b","journal-title":"Neurology"},{"key":"794_CR41","doi-asserted-by":"publisher","first-page":"1424","DOI":"10.1016\/j.mayocp.2015.07.019","volume":"90","author":"M Russo","year":"2015","unstructured":"Russo M, Guarneri C, Mazzon E, Sessa E, Bramanti P, Calabr\u00f2 RS (2015) Fingolimod-associated peripheral vascular adverse effects. Mayo Clin Proc 90:1424\u20131427. doi:\n                        10.1016\/j.mayocp.2015.07.019","journal-title":"Mayo Clin Proc"},{"key":"794_CR42","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1001\/archneurol.2012.1051","volume":"69","author":"EW Radue","year":"2012","unstructured":"Radue EW, O\u2019Connor P, Polman CH, Hohlfeld R, Calabresi P, Selmaj K, Mueller-Lenke N, Agoropoulou C, Holdbrook F, de Vera A, Zhang-Auberson L, Francis G, Burtin P, Kappos L, FTY720 Research Evaluating Effects of Daily Oral Therapy in Multiple Sclerosis (FREEDOMS) Study Group (2012) Impact of fingolimod therapy on magnetic resonance imaging outcomes in patients with multiple sclerosis. Arch Neurol 69:1259\u20131269","journal-title":"Arch Neurol"},{"key":"794_CR43","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1177\/1756285616628766","volume":"9","author":"BO Khatri","year":"2016","unstructured":"Khatri BO (2016) Fingolimod in the treatment of relapsing-remitting multiple sclerosis: long-term experience and an update on the clinical evidence. Ther Adv Neurol Disord 9:130\u2013147. doi:\n                        10.1177\/1756285616628766","journal-title":"Ther Adv Neurol Disord"},{"key":"794_CR44","doi-asserted-by":"publisher","first-page":"1654","DOI":"10.1212\/01.wnl.0000435293.34351.11","volume":"81","author":"G Pilz","year":"2013","unstructured":"Pilz G, Harrer A, Wipfler P, Wipfler P, Oppermann K, Sellner J, Fazekas F, Trinka E, Kraus J (2013) Tumefactive MS lesions under fingolimod: a case report and literature review. Neurology 81:1654\u20131658. doi:\n                        10.1212\/01.wnl.0000435293.34351.11","journal-title":"Neurology"},{"key":"794_CR45","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.jns.2014.06.013","volume":"344","author":"MA Hellmann","year":"2014","unstructured":"Hellmann MA, Lev N, Lotan I, Mosberg-Galili R, Inbar E, Luckman J, Fichman-Horn S, Yakimov M, Steiner I (2014) Tumefactive demyelination and a malignant course in an MS patient during and following fingolimod therapy. J Neurol Sci 344:193\u2013197. doi:\n                        10.1016\/j.jns.2014.06.013","journal-title":"J Neurol Sci"},{"key":"794_CR46","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.msard.2015.05.007","volume":"4","author":"MH Harirchian","year":"2015","unstructured":"Harirchian MH, Taalimi A, Siroos B (2015) Emerging tumefactive MS after switching therapy from interferon beta to fingolimod: a case report. Mult Scler Relat Disord 4:400\u2013402","journal-title":"Mult Scler Relat Disord"},{"key":"794_CR47","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1007\/s13760-015-0495-z","volume":"116","author":"S Boangher","year":"2016","unstructured":"Boangher S, Goffette S, Van Pesch V, Mespouille P (2016) Early relapse with tumefactive MS lesion upon initiation of fingolimod therapy. Acta Neurol Belg 116:95\u201397. doi:\n                        10.1007\/s13760-015-0495-z","journal-title":"Acta Neurol Belg"},{"key":"794_CR48","doi-asserted-by":"publisher","first-page":"2000","DOI":"10.1212\/WNL.0b013e3182735cb3","volume":"79","author":"F Visser","year":"2012","unstructured":"Visser F, Wattjes MP, Pouwels PJ, Linssen WH, van Oosten BW (2012) Tumefactive multiple sclerosis lesions under fingolimod treatment. Neurology 79:2000\u20132003. doi:\n                        10.1212\/WNL.0b013e3182735cb3","journal-title":"Neurology"},{"key":"794_CR49","doi-asserted-by":"publisher","first-page":"1650","DOI":"10.1177\/1352458512463768","volume":"18","author":"S Jander","year":"2012","unstructured":"Jander S, Turowski B, Kieseier BC, Hartung HP (2012) Emerging tumefactive multiple sclerosis after switching therapy from natalizumab to fingolimod. Mult Scler 18:1650\u20131652. doi:\n                        10.1177\/1352458512463768","journal-title":"Mult Scler"},{"key":"794_CR50","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1212\/WNL.0b013e31829deeb4","volume":"81","author":"MO Kinney","year":"2013","unstructured":"Kinney MO, McDonnell G (2013) Tumefactive multiple sclerosis lesions under fingolimod treatment. Neurology 81:403. doi:\n                        10.1212\/WNL.0b013e31829deeb4","journal-title":"Neurology"},{"key":"794_CR51","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1111\/cns.12563","volume":"22","author":"YD Fragoso","year":"2016","unstructured":"Fragoso YD, Sato HK (2016) Catastrophic magnetic resonance images in the central nervous system of patients undergoing treatment with fingolimod. CNS Neurosci Ther 22:633\u2013635. doi:\n                        10.1111\/cns.12563","journal-title":"CNS Neurosci Ther"},{"key":"794_CR52","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1177\/1756285615594575","volume":"8","author":"S Faissner","year":"2015","unstructured":"Faissner S, Hoepner R, Lukas C, Chan A, Gold R, Ellrichmann G (2015) Tumefactive multiple sclerosis lesions in two patients after cessation of fingolimod treatment. Ther Adv Neurol Disord 8:233\u2013238. doi:\n                        10.1177\/1756285615594575","journal-title":"Ther Adv Neurol Disord"},{"key":"794_CR53","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1212\/WNL.0b013e318248deea","volume":"78","author":"N Jain","year":"2012","unstructured":"Jain N, Bhatti MT (2012) Fingolimod-associated macular edema: incidence, detection, and management. Neurology 78:672\u2013680. doi:\n                        10.1212\/WNL.0b013e318248deea","journal-title":"Neurology"},{"key":"794_CR54","first-page":"12","volume":"17","author":"R Pul","year":"2016","unstructured":"Pul R, Osmanovic A, Schmalstieg H, Pielen A, Pars K, Schwenkenbecher P, S\u00fchs KW, Yildiz \u00d6, Frank B, Stangel M, Skripuletz T (2016) Fingolimod associated bilateral cystoid macular edema-wait and see? Int J Mol Sci 17(12):2106","journal-title":"Int J Mol Sci"},{"key":"794_CR55","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1016\/j.msard.2012.11.004","volume":"2","author":"OJ Coppes","year":"2013","unstructured":"Coppes OJ, Gutierrez I, Reder AT, Ksiazek S, Bernard J (2013) Severe early bilateral macular edema following fingolimod therapy. Mult Scler Relat Disord 2:256\u2013258. doi:\n                        10.1016\/j.msard.2012.11.004","journal-title":"Mult Scler Relat Disord"},{"key":"794_CR56","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1001\/jamaophthalmol.2013.570","volume":"131","author":"AR Afshar","year":"2013","unstructured":"Afshar AR, Fernandes JK, Patel RD, Ksiazek SM, Sheth VS, Reder AT, Hariprasad SM (2013) Cystoid macular edema associated with fingolimod use for multiple sclerosis. JAMA Ophthalmol 131:103\u2013107. doi:\n                        10.1001\/jamaophthalmol.2013.570","journal-title":"JAMA Ophthalmol"},{"key":"794_CR57","doi-asserted-by":"crossref","first-page":"e13","DOI":"10.1212\/NXI.0000000000000013","volume":"1","author":"V Li","year":"2014","unstructured":"Li V, Kane J, Chan HH, Hall AJ, Butzkueven H (2014) Continuing fingolimod after development of macular edema: a case report. Neurol Neuroimmunol Neuroinflamm 1:e13","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"794_CR58","first-page":"134636","volume":"2012","author":"L Liu","year":"2012","unstructured":"Liu L, Cuthbertson F (2012) Early bilateral cystoid macular edema secondary to fingolimod in multiple sclerosis. Case Rep Med 2012:134636","journal-title":"Case Rep Med"},{"key":"794_CR59","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1097\/WNO.0b013e31822bed20","volume":"31","author":"R Gallego-Pinazo","year":"2011","unstructured":"Gallego-Pinazo R, Espa\u00f1a-Gregori E, Casanova B, Pardo-L\u00f3pez D, Diaz-Llopis M (2011) Branch retinal vein occlusion during fingolimod treatment in a patient with multiple sclerosis. J Neuroophthalmol 31:292\u2013293","journal-title":"J Neuroophthalmol"},{"key":"794_CR60","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1097\/WNO.0b013e31829b42e1","volume":"33","author":"MT Bhatti","year":"2013","unstructured":"Bhatti MT, Freedman SM, Mahmoud TH (2013) Fingolimod therapy and macular hemorrhage. J Neuroophthalmol 33:370\u2013372. doi:\n                        10.1097\/WNO.0b013e31829b42e1","journal-title":"J Neuroophthalmol"},{"key":"794_CR61","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1186\/s12886-015-0125-9","volume":"15","author":"N Ueda","year":"2015","unstructured":"Ueda N, Saida K (2015) Retinal haemorrhages following fingolimod treatment for multiple sclerosis; a case report. BMC Ophthalmol 15:135","journal-title":"BMC Ophthalmol"},{"key":"794_CR62","doi-asserted-by":"publisher","DOI":"10.1038\/eye.2016.258","author":"P Mandal","year":"2016","unstructured":"Mandal P, Gupta A, Fusi-Rubiano W, Keane PA, Yang Y (2016) Fingolimod: therapeutic mechanisms and ocular adverse effects. Eye (Lond). doi:\n                        10.1038\/eye.2016.258","journal-title":"Eye (Lond)"},{"key":"794_CR63","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1212\/WNL.0000000000000137","volume":"82","author":"G Karlsson","year":"2014","unstructured":"Karlsson G, Francis G, Koren G, Heining P, Zhang X, Cohen JA, Kappos L, Collins W (2014) Pregnancy outcomes in the clinical development program of fingolimod in multiple sclerosis. Neurology 82:674\u2013680. doi:\n                        10.1212\/WNL.0000000000000137","journal-title":"Neurology"},{"key":"794_CR64","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1038\/nrneurol.2014.22","volume":"10","author":"B Jones","year":"2014","unstructured":"Jones B (2014) Multiple sclerosis: study reinforces need for contraception in women taking fingolimod. Nat Rev Neurol. 10:125. doi:\n                        10.1038\/nrneurol.2014.22","journal-title":"Nat Rev Neurol."},{"key":"794_CR65","doi-asserted-by":"publisher","first-page":"1411","DOI":"10.1111\/j.1476-5381.2012.01865.x","volume":"166","author":"LJ Spijkers","year":"2012","unstructured":"Spijkers LJ, Alewijnse AE, Peters SL (2012) FTY720 (fingolimod) increases vascular tone and blood pressure in spontaneously hypertensive rats via inhibition of sphingosine kinase. Br J Pharmacol 166:1411\u20131418. doi:\n                        10.1111\/j.1476-5381.2012.01865.x","journal-title":"Br J Pharmacol"},{"key":"794_CR66","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1016\/S1474-4422(14)70049-3","volume":"13","author":"PA Calabresi","year":"2014","unstructured":"Calabresi PA, Radue EW, Goodin D, Jeffery D, Rammohan KW, Reder AT, Vollmer T, Agius MA, Kappos L, Stites T, Li B, Cappiello L, von Rosenstiel P, Lublin FD (2014) Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Neurol. 13:545\u2013556. doi:\n                        10.1016\/S1474-4422(14)70049-3","journal-title":"Lancet Neurol."},{"issue":"10023","key":"794_CR67","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1016\/S0140-6736(15)01314-8","volume":"387","author":"F Lublin","year":"2016","unstructured":"Lublin F, Miller DH, Freedman MS, Cree BA, Wolinsky JS, Weiner H, Lubetzki C, Hartung HP, Montalban X, Uitdehaag BM, Merschhemke M, Li B, Putzki N, Liu FC, H\u00e4ring DA, Kappos L, INFORMS study investigators (2016) Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet 387(10023):1075\u20131084. doi:\n                        10.1016\/S0140-6736(15)01314-8","journal-title":"Lancet"},{"issue":"3","key":"794_CR68","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1016\/j.msard.2012.11.001","volume":"2","author":"RG Beran","year":"2013","unstructured":"Beran RG, Hegazi Y, Schwartz RS, Cordato DJ (2013) Rebound exacerbation multiple sclerosis following cessation of oral treatment. Mult Scler Relat Disord. 2(3):252\u2013255. doi:\n                        10.1016\/j.msard.2012.11.001","journal-title":"Mult Scler Relat Disord."},{"key":"794_CR69","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2014-206314","author":"R Alroughani","year":"2014","unstructured":"Alroughani R, Almulla A, Lamdhade S, Thussu A (2014) Multiple sclerosis reactivation postfingolimod cessation: is it IRIS? BMJ Case Rep. doi:\n                        10.1136\/bcr-2014-206314","journal-title":"BMJ Case Rep"},{"issue":"4","key":"794_CR70","doi-asserted-by":"publisher","first-page":"e247","DOI":"10.1212\/NXI.0000000000000247","volume":"3","author":"K Ikumi","year":"2016","unstructured":"Ikumi K, Ando T, Katano H, Katsuno M, Sakai Y, Yoshida M, Saida T, Kimura H, Sobue G (2016) HSV-2-related hemophagocytic lymphohistiocytosis in a fingolimod-treated patient with MS. Neurol Neuroimmunol Neuroinflamm. 3(4):e247. doi:\n                        10.1212\/NXI.0000000000000247","journal-title":"Neurol Neuroimmunol Neuroinflamm."}],"container-title":["Acta Neurologica Belgica"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s13760-017-0794-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13760-017-0794-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13760-017-0794-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,11,3]],"date-time":"2017-11-03T07:09:43Z","timestamp":1509692983000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s13760-017-0794-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5,20]]},"references-count":70,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["794"],"URL":"https:\/\/doi.org\/10.1007\/s13760-017-0794-7","relation":{},"ISSN":["0300-9009","2240-2993"],"issn-type":[{"value":"0300-9009","type":"print"},{"value":"2240-2993","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,5,20]]}}}